Nectar Lifesciences Limited has successfully concluded its postal ballot process, with shareholders approving three critical corporate governance resolutions. The company declared the results on March 01, 2026, following the completion of electronic voting on February 28, 2026.

Postal Ballot Results Overview

The postal ballot process covered three resolutions, with shareholders demonstrating strong support across all proposals. The voting was conducted entirely through electronic means, in compliance with regulatory requirements and MCA circulars.

Director Appointment Details

Shareholders approved the appointment of Mr. Sushil Kapoor (DIN: 00063525) in dual capacity. The first resolution appointed him as a Director liable to retire by rotation, while the second resolution designated him as Wholetime Director (Finance) for a three-year term effective December 04, 2025.

Remuneration Structure

The approved compensation package for Mr. Kapoor includes:

Voting Participation Analysis

The postal ballot witnessed significant participation from different shareholder categories. Out of total outstanding shares of 194260970, a total of 101808160 shares participated in the voting process, representing 52.41% participation.

Corporate Governance Process

The postal ballot process was conducted in strict compliance with the Companies Act, 2013, and SEBI regulations. Mr. Prince Chadha (ACS 32856) served as the scrutinizer for the electronic voting process. The company utilized the services of Kfin Technologies Limited as the Registrar and Share Transfer Agent for facilitating remote e-voting.

The voting period extended from 9:00 A.M. on January 30, 2026, to 5:00 P.M. on February 28, 2026. Electronic copies of the postal ballot notice were distributed on January 28, 2026, to shareholders whose email addresses were registered with the company or depositories.

MOA Amendments

The third resolution involved adopting a new set of Memorandum of Association with amended object clauses. This special resolution received approval from 99.08% of the votes polled, enabling the company to expand its business objectives through additional sub-clauses in the main object clause.

All resolutions were declared passed with the requisite majority, and the results have been communicated to stock exchanges where the company's shares are listed. The formal documentation was completed at the company's registered office in Dera Bassi, Punjab, on March 13, 2026.

Nectar Lifesciences Limited has announced the execution of an inter-corporate loan agreement with its wholly owned subsidiary Avensis Exports Private Limited (AEPL) for INR 100 crores. The company informed stock exchanges about this development on March 12, 2026, in compliance with SEBI listing regulations.

Loan Agreement Details

The inter-corporate loan agreement was executed on March 11, 2026, between Nectar Lifesciences as the lender and Avensis Exports Private Limited as the borrower. The arrangement involves an unsecured loan facility with specific terms designed to support the subsidiary's operational requirements.

Purpose and Utilization

The borrower will utilize the loan amount towards general corporate purposes and business requirements. This funding arrangement is expected to support Avensis Exports Private Limited's operational activities and strategic initiatives as a wholly owned subsidiary of Nectar Lifesciences.

Related Party Transaction Framework

The transaction qualifies as a related party transaction since Avensis Exports Private Limited is a wholly owned subsidiary of Nectar Lifesciences Limited. However, the company has confirmed that the transaction is conducted at arm's length pricing, ensuring compliance with regulatory requirements.

Regulatory Compliance

The loan agreement disclosure was made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company provided comprehensive details as required under the SEBI Master Circular dated January 30, 2026, ensuring full transparency with stakeholders.

The agreement does not contain provisions for director appointment rights, share subscription preferences, or capital structure change restrictions. This straightforward loan arrangement focuses on providing financial support to the subsidiary while maintaining regulatory compliance and corporate governance standards.